Incyte earns $19M milestone from Lilly

Wilmington, DE-based Incyte says that it earned a rich $19 million milestone from Eli Lilly after the pharma company launched the Phase IIb study of the rheumatoid arthritis drug INCB28050. Lilly inked a licensing pact covering Incyte's oral JAK1 and JAK2 inhibitor. The compound will now be referred to as LY3009104. Incyte release

Suggested Articles

What a difference a day makes in biotech.

A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing.

A drug developed at Temple restores a mechanism in brain cells that prevents the toxic buildup of the proteins amyloid beta and tau in Alzheimer's.